Pulmonx Corp reports results for the quarter ended June 30 - Earnings Summary

• Pulmonx Corp LUNG reported a quarterly adjusted loss of 38 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of six analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -42 cents to -38 cents per share.

• Revenue rose 14.8% to $23.86 million from a year ago; analysts expected $23.47 million.

• Pulmonx Corp's reported EPS for the quarter was a loss of 38 cents​.

• The company reported a quarterly loss of $15.17 million.

• Pulmonx Corp shares had risen by 19.3% this quarter and lost 54.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Pulmonx Corp is $13.50, about 77.1% above its last closing price of $3.09

This summary was machine generated from LSEG data July 30 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)